LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

80.99 +2.03 (+2.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

1 Cash-Heavy Stock That Stand Out and 2 to Question

May 09, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

May 06, 2025

Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season.

Via StockStory

Topics Artificial Intelligence Economy

Why LeMaitre (LMAT) Shares Are Sliding Today

May 02, 2025

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 12.2% in the afternoon session after the company reported weak first quarter 2025 results with a significant miss on full-year EPS...

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Novocure Stock Earns 96 RS Rating ↗

December 03, 2024

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.

Via Investor's Business Daily

In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular ↗

November 01, 2024

Via Benzinga

Analyst Scoreboard: 4 Ratings For LeMaitre Vascular ↗

October 15, 2024

Via Benzinga

LeMaitre’s (NASDAQ:LMAT) Q1: Beats On Revenue, Guides for Strong Full-Year Sales

May 01, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next...

Via StockStory

A Look at LeMaitre Vascular's Upcoming Earnings Report ↗

April 30, 2025

Via Benzinga

Earnings To Watch: LeMaitre (LMAT) Reports Q1 Results Tomorrow

April 30, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

1 Profitable Stock with Impressive Fundamentals and 2 to Steer Clear Of

April 28, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Navigating 4 Analyst Ratings For LeMaitre Vascular ↗

May 31, 2024

Via Benzinga

Q4 Earnings Highlights: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

April 17, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at LeMaitre (NASDAQ:LMAT) and the best and...

Via StockStory

Topics Artificial Intelligence Economy

3 Healthcare Stocks Facing Headwinds

April 16, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & Consumables - Specialty Stocks In Q4

April 15, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - specialty stocks fared in...

Via StockStory

Topics Artificial Intelligence Economy

Why LEMAITRE VASCULAR INC (NASDAQ:LMAT) qualifies as a quality stock. ↗

April 11, 2025

A fundamental analysis of (NASDAQ:LMAT): Why Quality Investors May Find LEMAITRE VASCULAR INC (NASDAQ:LMAT) Attractive.

Via Chartmill

2 Reasons to Avoid LMAT and 1 Stock to Buy Instead

March 31, 2025

Over the past six months, LeMaitre’s shares (currently trading at $83.18) have posted a disappointing 10.5% loss while the S&P 500 was down 4.1%. This may have investors wondering how to approach the...

Via StockStory

Topics Stocks Supply Chain

Winners And Losers Of Q4: Integra LifeSciences (NASDAQ:IART) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

March 27, 2025

Looking back on surgical equipment & consumables - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Integra LifeSciences (NASDAQ:IART) and its peers.

Via StockStory

Topics Artificial Intelligence Economy

Q4 Earnings Review: Surgical Equipment & Consumables - Specialty Stocks Led by Intuitive Surgical (NASDAQ:ISRG)

March 24, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Intuitive...

Via StockStory

Topics Artificial Intelligence Economy

LeMaitre (NASDAQ:LMAT) Misses Q4 Sales Targets, Stock Drops 11%

February 27, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of...

Via StockStory

What To Expect From LeMaitre’s (LMAT) Q4 Earnings

February 26, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results tomorrow after the bell. Here’s what to expect.

Via StockStory

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 17, 2024

Via Benzinga

Inari Medical Stock Gets RS Rating Upgrade ↗

December 11, 2024

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

Via Investor's Business Daily

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year ↗

November 18, 2024

ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.

Via Investor's Business Daily

Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 01, 2024

Via Benzinga

This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 15, 2024

Via Benzinga

LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024 ↗

August 01, 2024

LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Staar Surgical Stock Earns RS Rating Upgrade ↗

June 27, 2024

On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77.

Via Investor's Business Daily

Stryker Stock Sees RS Rating Treks Higher To 71 ↗

May 29, 2024

Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.